# Retatrutide's July 23 Phase 3 Readout Keeps Raising the Ceiling
> Note: PeptIQ is not a medical provider. This article is for educational purposes only. Always work with a qualified clinician before starting, stopping, or changing any treatment.
Eli Lilly's July 23 retatrutide update was not subtle.
TRIUMPH-2 and TRIUMPH-3 both hit their primary endpoints, and the top-line numbers keep retatrutide in a category of its own. The 12 mg arm reached 20.8% average body weight loss in adults with obesity or overweight and type 2 diabetes, and 22.6% in adults with severe obesity and established cardiovascular disease.
Those are not just strong numbers. They are the kind of numbers that shift the frame of the conversation.
> Phase 1 proved feasibility. Phase 2 proved depth. Phase 3 proved the effect holds up when the population gets harder.
Use the phase switcher above to move through the story in order: feasibility, depth, then durability.
The New Phase 3 Numbers
Here is the new July 23 data in plain language:
- TRIUMPH-2: 20.8% average weight loss at 80 weeks with 12 mg, plus A1C reductions up to 1.6 percentage points
- TRIUMPH-3: 22.6% average weight loss at 80 weeks with 12 mg
- The most common adverse events were gastrointestinal and generally mild to moderate
- Lilly plans to submit its BLA to the FDA in Q1 2027
The TRIUMPH-2 population had obesity or overweight plus type 2 diabetes, which makes the weight-loss result especially relevant because it came in a harder-to-treat metabolic group.
The TRIUMPH-3 population had severe obesity and established cardiovascular disease, so that readout matters because it speaks to a higher-risk cardiometabolic cohort.
The Story Arc In One Line
Retatrutide moved from interesting to undeniable by doing the same thing across each phase, just at larger scale and in harder patients.
That is why this molecule keeps getting attention. It keeps clearing the next bar.
The Timeline That Matters
| Stage | What it answered | Why it mattered |
|---|---|---|
| Phase 1 | Does the drug behave like a weekly human therapy? | It established feasibility and dose response. |
| Phase 2 | Does the effect remain deep over time? | It showed 24.2% at 48 weeks at the top dose. |
| Phase 3 | Does the result hold in tougher populations? | It delivered 20.8% and 22.6% in large pivotal trials. |
How The Story Started In Phase 1
Retatrutide did not become interesting in phase 3. Phase 3 just confirmed what phase 1 hinted at.
The first-in-human work used a multiple ascending dose design over 12 weeks. The study tested once-weekly subcutaneous doses from 0.5 mg up to 12 mg and showed a clear dose-response signal.
That early data mattered for two reasons:
- It showed retatrutide was biologically active in humans
- It showed the effect was dose-dependent, not random noise
The phase 1 readout was not about giant headline weight-loss numbers. It was about proving the mechanism was doing what Lilly expected, while staying within a tolerability range that made weekly dosing plausible.
That is the boring part that makes later success possible.
What Phase 2 Added
Phase 2 turned the signal into a shape.
Lilly's NEJM-published phase 2 study showed:
- 17.5% mean weight reduction at 24 weeks with the highest dose
- 24.2% mean weight reduction at 48 weeks with the highest dose
- Dose-dependent improvement in glycemic markers
- GI side effects that were common but usually manageable
That was the moment the molecule stopped looking like a clever concept and started looking like a serious obesity drug candidate.
The phase 2 numbers also made the later phase 3 results easier to interpret. Retatrutide was not just producing a short-lived appetite effect. It was sustaining a deep response over time.
Why Retatrutide Keeps Winning The Comparison
Retatrutide is a triple agonist. It hits:
